Prasugrel HCl (Prasugrel HCl)
Overview of Prasugrel HCl
Prasugrel is an anti-platelet agent. The chemical name is 5-[(1RS)-2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]- 4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate hydrochloride corresponding to the molecular formula C20H20FNO3S�HCl. Prasugrel is a prodrug, oxidation by intestinal and hepatic cytochrome P-450 enzymes convert prasugrel into its active metabolite. Its active form binds irreversibly to the adenosine diphosphate (ADP) P2Y12 receptor on platelets for their lifespan, thereby inhibiting their activation and decreasing subsequent platelet aggregation.
Indication of Prasugrel HCl
Prasugrel HCl is primarily indicated in conditions like Acute coronary syndrome (without st-segment elevation), Coronary artery disease, Myocardial infarction, Myocardial infarction (non st-segment elevation), Unstable angina.
Contraindication of Prasugrel HCl
Prasugrel HCl is contraindicated in conditions like Bleeding,Transient ischaemic attacks.
Side Effects of Prasugrel HCl
Prasugrel HCl produces potentially life-threatening effects which include Thrombocytopenia, Bleeding, Hypersensitivity, blood in urine, blood in stool, Peripheral edema, Thrombotic thrombocytopenic purpura, Jaundice, Atrial fibrillation. which are responsible for the discontinuation of Prasugrel HCl therapy.,The signs and symptoms that are produced after the acute overdosage of Prasugrel HCl include Vomiting, Blurred vision, hepatocellular atrophy, Shortness of breadth, Mydriasis, Decreased locomotor activity, Lacrimation.,The symptomatic adverse reactions produced by Prasugrel HCl are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Tiredness, Nausea, Diarrhea, Dyspnea, Hypotension, Cough, Pain in upper & lower extremities, Back pain, Mild headache, Minor chest pain, Abnormal hepatic function.
Precautions of Prasugrel HCl
It can cause significant, sometimes fatal, bleeding. Do not use in patients with active pathological bleeding or a history of transient ischemic attack or stroke. In patients greater then or equal to 75 years of age, it is generally not recommended because of the increased risk of fatal and intracranial bleeding and uncertain benefit, except in high-risk patients (diabetes or prior MI), where its effect appears to be greater and its use may be considered. Do not start Prasugrel in patients likely to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue it at least 7 days prior to any surgery. Additional risk factors for bleeding include: Body weight < 60 kg Propensity to bleed Concomitant use of medications that increase the risk of bleeding. Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, Percutaneous coronary intervention (PCI), CABG, or other surgical procedures in the setting of Prasugrel. If possible, manage bleeding without discontinuing it. Stopping Prasugrel, particularly in the first few weeks after acute coronary syndrome, increases the risk of subsequent cardiovascular events .